Medicare Part B Step Therapy Bevacizumab-Oncology Products
Customize your policy alerts
Sign up for zing_health Policy 6927-D alerts
Get alerted when Policy 6927-D changes without checking for updates manually.
Monitor payer policy activity
This policy governs Medicare Part B coverage of preferred and non-preferred bevacizumab-oncology products for Zing Health members. Non-preferred products require a clinical exception through prior authorization, subject to step-therapy criteria and applicable Medicare coverage and utilization-management requirements.
No material clinical or coverage changes in this revision.
Non-Preferred Product Coverage Exceptions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.